Syros Pharmaceuticals, Inc.

OTCPK:SYRS 주식 리포트

시가총액: US$5.4k

Syros Pharmaceuticals 향후 성장

Future 기준 점검 0/6

현재 Syros Pharmaceuticals 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

핵심 정보

n/a

이익 성장률

n/a

EPS 성장률

Biotechs 이익 성장25.3%
매출 성장률n/a
향후 자기자본이익률n/a
애널리스트 커버리지

None

마지막 업데이트n/a

최근 향후 성장 업데이트

Recent updates

Seeking Alpha • Jul 02

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

Summary Syros Pharmaceuticals focuses on developing therapies for myeloid cancers. The main pipeline candidate is tamibarotene, with positive signals in phase 2 trial and a key data readout coming in Q4 2024. Financially, SYRS has $112.2 million in assets, but faces a high cash burn rate and potential need for more financing. Read the full article on Seeking Alpha
Seeking Alpha • Jan 14

Syros Pharmaceuticals: Rising Despite Dilution, A Must Look

Summary Syros Pharmaceuticals is a cancer-focused biotech working on therapies for blood cancer, with a main drug in development. The company's main program is tamibarotene, targeting specific myeloid cancers with high RARA gene expression. Syros has encouraging data from a phase 2 trial and is currently conducting a phase 3 trial, but lack of asset diversification and high risk should be considered. Read the full article on Seeking Alpha
Seeking Alpha • Sep 20

Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders

Summary Syros Pharmaceuticals has recently acquired its peer Tyme Technologies. The sole purpose of the merger was to acquire TYME's cash balance. Concurrently with the merger, the largest shareholders put in an additional $130m into the company at over 30% premium to current prices. This strong vote of confidence from insiders makes SYRS very interesting, especially when shares are below insiders' entry price. SYRS share price has just declined by 17%, presenting an attractive entry point. SYRS now trades materially below net cash while being fully funded to bring development programs to fruition. The merger between Syros Pharmaceuticals (SYRS) and Tyme Technologies (TYME) was announced in the beginning of July and closed last Friday. This opportunity attracted our interest purely from the merger arb perspective but it actually had two angles to it (with the second one being the key point of this article): Pure merger arbitrage play - pretty much till the closing the spread on the merger stood at 20-40% (chart below) and we could not see any real risks in this transaction despite our best efforts to dig something out. Although such a wide spread on a merger with limited risks might seem too-good-to-true, we actually spot similar opportunities quite often in the less analyzed microcap space and cover them on our premium service Special Situation Investing. The merger arb aspect of the transaction has now fully played out, but there is another angle to the story. Another angle of TYME / SYRS transaction is that SYRS is a very well-positioned pharma company with an attractive development portfolio and this merger simply was an opportunity to acquire SYRS at 20-30% discount to the prevailing market prices by buying it through TYME. Now that the merger closed, one can no longer acquire TYME stock with hopes it will convert to SYRS, but luckily enough SYRS is now itself trading materially below the levels of the merger announcement, presenting an equally attractive opportunity as was acquiring it through TYME. Why the wide spread on the merger? Note: You can easily skip to the next section as this one only looks at a strange market inefficiency in these types of situations. TYME/SYRS Merger Spread Despite our attempts to find an explanation for this wide 20-40% spread, we could not find anything. So in the end we concluded that this is one of those micro-cap merger arbitrage situations where the market is simply not paying attention and our research actually gives us an edge. We love these types of opportunities and covered these regularly on Special Situation Investing. The spread on SYRS / TYME merger seemed completely overblown given the short expected closing timeline, persistently cheap SYRS hedging fees and very low risk of merger termination. The merger was basically an equity raise for SYRS. The buyer openly stated that it was interested solely in TYME's net cash position ($60m) to enhance its liquidity and indicated that TYME's existing drug development program will be put on hold. Shareholder approvals seemed guaranteed as around 35% of SYRS and 30% of TYME shares had already been in support. The PIPE financing for an additional $130m from the largest shareholders at a premium to the market prices added further confidence that every single party of the transaction wants this to close successfully. As expected, shareholder approvals were received on the 15th of September and the merger closed a day later. As further proof of market inefficiency in these types of situations, the spread still persisted even after the shareholder approval. After the vote SYRS issued an announcement stating that the merger will close the next day but the spread persisted and even increased slightly to 10%. Only by the end of the day the spread was finally eliminated. What's next for SYRS? Note: post-merger closing, SYRS has effected a 10-to-1 reverse stock split. Further calculations refer to SYRS's share price and count after the split. Aside from raising cash through the merger with TYME, SYRS also simultaneously did a huge $130m PIPE (vs $50m market cap at the time) at $0.94/share ($9.40/share adjusted for the recent split). The participants were mostly major shareholders of the company - large and reputable PE firms including Bain Capital, Invus Public Equities, Ally Bridge MedAlpha, and others. SYRS co-founder and founding investor Flagship Pioneering also participated. The fact that these firms, who have significantly more knowledge and information about the SYRS pipeline have put that much money at over 30% premium to current prices adds significant confidence in the value of the company's current pipeline. It's no secret that biopharma investing is largely a gamble. However, one thing for sure is that such reputable firms do not like throwing good money after the bad, and especially not in this size. Both transactions have now provided SYRS with enough cash runway through 2025. Post-merger, SYRS has 27.9m of outstanding shares and total cash of ~$240m (after deducting transaction expenses). Net cash is at ~$200m or ~$7.16 per SYRS share. SYRS is down 17% on the first day after the merger close and now sits close to an all-time-low at $6.08/share. The stock is currently trading 15% below net cash and over 35% discount to where the largest shareholders have just made a material investment. SYRS Net Cash Before the merger, SYRS used to trade at up to 8-10% discount to net cash. However, right now the company is in much better shape - a very strong cash position and no financing/dilution risk until 2026 - should be enough to advance its main treatment Tamibarotene into commercialization. If Tamibarotene shows good phase 3 results, the upside from current levels will be very material. These points, as well as the recent vote of confidence from major shareholders, suggest that 15% discount to net cash is overly punitive.
Seeking Alpha • Sep 13

Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609

Syros Pharmaceuticals (NASDAQ:SYRS) on Tuesday said the U.S. FDA had granted an orphan drug designation to its inhibitor SY-5609 for the treatment of pancreatic cancer. SY-5609 is currently being assessed in combination with chemotherapy for the treatment of patients with relapsed metastatic pancreatic cancer, SYRS said in a statement. The FDA's orphan drug designation program expedites the development and evaluation of a drug or biological product to prevent a rare disease or condition. SYRS stock +4.5% to $0.80 after hours.
Seeking Alpha • Aug 08

Syros Pharmaceuticals Q2 2022 Earnings Preview

Syros Pharmaceuticals (NASDAQ:SYRS) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.41 (-13.9% Y/Y) and the consensus Revenue Estimate is $4.78M (-7.4% Y/Y). Over the last 1 year, SYRS has beaten EPS estimates 50% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 3 upward revisions and 0 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

이 섹션에서는 일반적으로 전문 애널리스트들의 컨센서스 추정치를 기반으로 매출 및 이익 성장 전망을 제시하여 투자자들이 회사의 수익 창출 능력을 이해하도록 돕습니다. 그러나 Syros Pharmaceuticals는 과거 데이터가 충분하지 않고 애널리스트 예측도 없어, 과거 데이터를 단순히 외삽하거나 애널리스트 전망을 사용하여 향후 이익을 신뢰할 수 있게 계산할 수 없습니다.

Simply Wall St가 다루는 기업 중 97%는 과거 재무 데이터를 보유하고 있기 때문에, 이는 상당히 드문 상황입니다.

이익 및 매출 성장 예측

OTCPK:SYRS - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
9/30/20240-98-100-100N/A
6/30/20244-132-111-111N/A
3/31/20247-144-104-104N/A
12/31/202310-165-110-110N/A
9/30/20239-105-123-122N/A
6/30/20239-95-127-126N/A
3/31/202312-93-131-130N/A
12/31/202215-95-124-123N/A
9/30/202223-114-116-115N/A
6/30/202225-109-108-107N/A
3/31/202224-97-109-108N/A
12/31/202123-87-101-100N/A
9/30/202121-93-108-106N/A
6/30/202120-86-95-94N/A
3/31/202118-81-81-80N/A
12/31/202015-84-61-57N/A
9/30/202010-74-50-38N/A
6/30/20207-74-48-34N/A
3/31/20204-76-54-40N/A
12/31/20192-75-73-60N/A
9/30/20192-74-68-63N/A
6/30/20192-70-65-62N/A
3/31/20192-64-60-58N/A
12/31/20182-62-42-40N/A
9/30/20181-60-38-37N/A
6/30/20181-58N/A-37N/A
3/31/20180-57N/A-34N/A
12/31/20171-54N/A-45N/A
9/30/20171-50N/A-44N/A
6/30/20171-50N/A-43N/A
3/31/20171-51N/A-43N/A
12/31/20160-51N/A-41N/A
9/30/2016N/A-52N/A-39N/A
6/30/2016N/A-48N/A-35N/A
3/31/20160-41N/A-30N/A
12/31/20150-35N/A-23N/A
9/30/20150-28N/A-18N/A

애널리스트 향후 성장 전망

수입 대 저축률: SYRS 의 예상 수익 증가율이 절약률(3.5%)보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: SYRS 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: SYRS 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: SYRS 의 수익이 US 시장보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 매출: SYRS 의 수익이 연간 20%보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: SYRS의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/22 11:41
종가2026/05/22 00:00
수익2024/09/30
연간 수익2023/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Syros Pharmaceuticals, Inc.는 4명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Mark BreidenbachOppenheimer & Co. Inc.
Zegbeh JallahRoth Capital Partners
Philip NadeauTD Cowen